BioAge reported early Phase 1 data for its inflammation-targeting candidate BGE-102, showing a rapid reduction in high-sensitivity C-reactive protein (hs-CRP) in people with obesity and elevated inflammation. The company said the 60 mg dose produced an 86% hs-CRP reduction after three weeks, with a majority of patients reaching hs-CRP levels below a commonly used threshold associated with lower cardiovascular complication risk. The update arrives as inflammation becomes an increasingly prioritized mechanism across cardio-metabolic drug development, with multiple programs seeking to translate biomarker movement into clinical outcome studies. For investors and operators, the readout is a near-term validation of pharmacodynamic effect, positioning the program for the next steps in proof-of-concept refinement.